Virpax Pharmaceuticals nasdaq Vrpx Stock Skyrockets on Positive Pain Relief Study Findings

Virpax Pharmaceuticals (NASDAQ: VRPX) Stock Skyrockets On Positive Pain Relief Study Findings

Virpax Pharmaceuticals stock (NASDAQ: VRPX) soared during intraday trading Wednesday after the company reported promising pain relief study results.

Virpax Pharmaceuticals has reported promising results from a pilot study of its pain management product, Probudur, a long-acting liposomal bupivacaine formulation. The study aimed to evaluate the pharmacokinetics and safety of Probudur when administered subcutaneously using a Swine Model.

Study Findings

The research involved administering a 30 mg/kg dose of Probudur to four juvenile domestic pigs. The study findings indicated that the drug was well-tolerated and exhibited a prolonged, slow-release profile without adverse effects. The histopathological examination of the injection sites provided additional confirmation regarding the tolerability of the product.

Probudur aims to reduce or eliminate the need for opioid use post-surgery by blocking pain signals to the brain. Previous pre-clinical studies have shown that the drug can provide pain relief for up to 96 hours, with some models suggesting analgesic effects lasting up to five days. In vitro studies have also indicated a slow release of up to six days.

Gerald Bruce, CEO of Virpax Pharmaceuticals, expressed confidence in the study results, stating,

“Our study results to date for Probudur, as expected, have consistently been positive and support our belief that Probudur has the potential to provide both immediate relief as well as sustained relief at the wound site.”

Bruce confirmed that the company is advancing negotiations for additional funding from a new institutional investor and remains on track to submit an Investigational New Drug Application (IND) for Probudur by the end of the year.

The development of Probudur underscores Virpax’s commitment to developing non-addictive solutions for pain management. In addition to Probudur, Virpax is progressing with other prescription drug candidates such as Envelta for acute and chronic pain, and NobrXiol for rare pediatric epilepsy. Nonprescription products in their pipeline include AnQlar for viral replication inhibition and Epoladerm for osteoarthritis pain.

Virpax Pharmaceuticals Stock (NASDAQ: VRPX) Reaction

VRPX stock surged 46.55% on Wednesday, closing at $1.70, marking a 220.69% increase for the week. The trading volume was 117,184,984 shares, significantly higher than the average daily volume of 4.75 million.